Craig Woods (Talk | contribs) m |
Craig Woods (Talk | contribs) |
||
Line 67: | Line 67: | ||
<h2>Temperate phage models</h2> | <h2>Temperate phage models</h2> | ||
<h3>Why consider a temperate phage?</h3> | <h3>Why consider a temperate phage?</h3> | ||
− | <p>One of the biggest issues surrounding <em> | + | <p>One of the biggest issues surrounding <em>Clostridium difficile</em> infection, is that of reinfection. We originally planned on using a temperate phage, modified so that it could not enter the lytic cycle, with the hope that a stable population of non-toxigenic lysogens (see lab pages for how we developed non-toxigenic <em>C. difficile</em>) would be formed that could outcompete toxigenic <em>C.difficile</em> strains [10]. Hence, we wanted to model the interaction between our engineered temperate phage and bacteria to see if a steady state could be reached and what conditions would be necessary for this to occur. We also wanted to see the time difference in effective treatment between a lytic and temperate phage to ensure that we did not sacrifice speed of treatment in order to prevent reinfection. We later decided to see what would happen if we allowed for phage to undergo induction.</p> |
<p>Click on the links below to see our results for both models.</p> | <p>Click on the links below to see our results for both models.</p> | ||
Line 87: | Line 87: | ||
<h2>Comparison of models</h2> | <h2>Comparison of models</h2> | ||
+ | <p>In this section we compare lytic and temperate phage models in order to direct the phage modification strategy employed in the laboratory. We wanted to predict whether it would be beneficial to produce a strictly temperate phage or whether the natural lytic cycle of the phage should be left untouched. The models were compared in terms of the proportion of lysogens to toxigenic bacteria, the speed of action and the potential for phage to remain in the system to prevent reinfection. </p> | ||
+ | |||
+ | <p>Click on the link below to see our model comparison.</p> | ||
+ | |||
<a class="ui button" href="https://2018.igem.org/Team:Nottingham/Comparison"> | <a class="ui button" href="https://2018.igem.org/Team:Nottingham/Comparison"> | ||
View section | View section | ||
Line 95: | Line 99: | ||
<h2>Methodology</h2> | <h2>Methodology</h2> | ||
+ | <p>In this section we focus on finding and classifying equilibrium points for two types of system, one with the ability to induce a lytic life cycle and one which models a strictly temperate phage. This information is important as it allows us to identify the conditions that must be satisfied by a phage in order to lead to a long term population of lysogens and free phage</p> | ||
+ | |||
+ | <p>Click on the link below to see expanded methodology.</p> | ||
+ | |||
<a class="ui button" href="https://2018.igem.org/Team:Nottingham/Methodology"> | <a class="ui button" href="https://2018.igem.org/Team:Nottingham/Methodology"> | ||
View section | View section | ||
Line 102: | Line 110: | ||
<div class="ui segment"> | <div class="ui segment"> | ||
<h2>Parameters</h2> | <h2>Parameters</h2> | ||
+ | <p>The utility of a model is strongly dependent upon the parameters used. Some of the parameters used were acquired from relevant literature while others were determined experimentally in the laboratory. One key parameter was that of decay rate which an analysis of phage literature revealed to be strongly positively correlated with burst size. This correlation allowed us to estimate the decay rate from a burst size assay we conduct on our phage phiSBRC. </p> | ||
+ | |||
+ | <p>Click on the link below for details on the parameters used in these models. </p> | ||
+ | |||
<a class="ui button" href="https://2018.igem.org/Team:Nottingham/Parameters"> | <a class="ui button" href="https://2018.igem.org/Team:Nottingham/Parameters"> | ||
View section | View section | ||
Line 109: | Line 121: | ||
<div class="ui segment"> | <div class="ui segment"> | ||
− | <h2>Achievements</h2> | + | <h2>Achievements</h2> |
+ | <p>This section summarises the achievements of the modelling efforts, allowing us to infer some key information which we can integrate into the design of the overall project, such as indicating the strategy which would lead to the most effective and cost efficient means of dosing patients with phage. </p> | ||
+ | |||
+ | <p>Click on the link below to see all key achievements.</p> | ||
+ | |||
<a class="ui button" href="https://2018.igem.org/Team:Nottingham/Modelling_achievements"> | <a class="ui button" href="https://2018.igem.org/Team:Nottingham/Modelling_achievements"> | ||
View section | View section | ||
Line 117: | Line 133: | ||
<div class="ui segment"> | <div class="ui segment"> | ||
<h2>References</h2> | <h2>References</h2> | ||
+ | <p>All scientific literature used in the generation of the model is accredited below.</p> | ||
+ | |||
+ | <p>Click on the link below to see the full list of references.</p> | ||
+ | |||
<a class="ui button" href="https://2018.igem.org/Team:Nottingham/Modelling_references"> | <a class="ui button" href="https://2018.igem.org/Team:Nottingham/Modelling_references"> | ||
View section | View section |
Revision as of 19:21, 17 October 2018